Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.
Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. Chan JA, et al. Among authors: zhu ax. Ann Oncol. 2011 Jun;22(6):1367-1373. doi: 10.1093/annonc/mdq604. Epub 2011 Jan 7. Ann Oncol. 2011. PMID: 21217058 Free PMC article. Clinical Trial.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Willett CG, et al. Among authors: zhu ax. Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25. Nat Med. 2004. PMID: 14745444 Free PMC article. Clinical Trial.
Combined modality treatment for rectal cancer.
Zhu AX, Willett CG. Zhu AX, et al. Semin Oncol. 2005 Feb;32(1):103-12. doi: 10.1053/j.seminoncol.2004.09.032. Semin Oncol. 2005. PMID: 15726512 Review.
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Willett CG, et al. Among authors: zhu ax. J Clin Oncol. 2005 Nov 1;23(31):8136-9. doi: 10.1200/JCO.2005.02.5635. J Clin Oncol. 2005. PMID: 16258121 Clinical Trial. No abstract available.
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP Jr, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG. Eder JP Jr, et al. Among authors: zhu ax. Cancer Chemother Pharmacol. 2006 Jul;58(1):107-16. doi: 10.1007/s00280-005-0134-0. Epub 2005 Dec 13. Cancer Chemother Pharmacol. 2006. PMID: 16362299 Clinical Trial.
397 results